Researchers
Mitchell Sabloff

Mitchell Sabloff

MSc, MDCM, FRCPC

Clinician Investigator, Cancer Research

Ottawa Hospital Research Institute

Director of the Ottawa Hospital Leukemia Program, Division of Hematology

The Ottawa Hospital

Co-Director of the Ottawa Hospital Hematology Bio-Bank, Division of Hematology

Ottawa Hospital Research Institute

Member of the Blood and Marrow Transplant Program, Division of Hematology

The Ottawa Hospital

Associate Professor, Department of Medicine

University of Ottawa

Contact

msabloff@ottawahospital.on.ca

613-737-8899 x79670

ORCID 0000-0002-0122-6138

Bio

Dr. Sabloff is the Director of the Leukemia Program, co-director of the Ottawa hospital hematology Biobank and is a member of the Blood and Marrow Transplant Program at the Ottawa Hospital. He has been working with Cancer Care Ontario on improving the care of patients with acute leukemia, across the province. Locally he has been collaborating with the Stanford lab at the Ottawa hospital research institute to identify patients who are have refractory AML and initiate clinical trials with novel therapies to improve their outcomes.

Research Goals and Interests

His research interests include refractory acute leukemia. He collaborates with a number of cooperative groups both in Canada and in North America. Locally he has helped identify a biomarker identifying patients who will be refractory to induction therapy and a drug that can improve the outcome of these patients. he is currently working on starting a trial using this biomarker and drug to better treat patients with refractory AML. he is currently the PI of the SIERRA trial for older patients w2ith refractory leukemia and has enrolled our first pt.

News

Publications

Incidence of Tumour Lysis Syndrome in Patients with Acute Myeloid Leukemia During Initiation of Therapy with Azacitidine and Venetoclax: A Retrospective Chart Review from a Canadian Single-Centre Perspective

2025-04-02 Go to publication

Patient and Healthcare Professional Reflections on Consenting for Extra Bone Marrow Samples to a Biobank for Research—A Qualitative Study

2025-03-01 Go to publication

Developing Organizational Requirements to Standardize Delivery and Improve Quality of Acute Leukemia Care in Ontario

2024-08-15 Go to publication

Younger Matched Unrelated Donors Confer Decreased Relapse Risk Compared to Older Sibling Donors in Older Patients with B Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

2023-10-01 Go to publication

Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid Leukemia

2023-09-01 Go to publication
View More on ORCiD

Related Research at The Ottawa Hospital